Chemistry:NITD008
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | NITD008 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H14N4O4 |
| Molar mass | 290.279 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus.[1][2][3] However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.[4]
See also
- Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients
- MK-608, a drug with a similar structure
- Remdesivir , FDA approved antiviral drug with a similar structure
- Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986
References
- ↑ "An adenosine nucleoside inhibitor of dengue virus". Proceedings of the National Academy of Sciences of the United States of America 106 (48): 20435–9. December 2009. doi:10.1073/pnas.0907010106. PMID 19918064. Bibcode: 2009PNAS..10620435Y.
- ↑ "In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses". Antiviral Research 130: 46–9. June 2016. doi:10.1016/j.antiviral.2016.03.013. PMID 27016316.
- ↑ "Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus". Open Forum Infectious Diseases 3 (4): ofw175. October 2016. doi:10.1093/ofid/ofw175. PMID 27747251.
- ↑ "Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection". Antiviral Research 122: 39–45. October 2015. doi:10.1016/j.antiviral.2015.07.008. PMID 26225754.
 |  |
